YJYixin Jiao

Yixin Jiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yixin Jiao has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older

    by Rowan McEvoy, Jessica Rose Hervol, Yike Zhang, Emma M. Wagner, Arnstein Lindaas, Yixin Jiao, Stanley Xu, Eric S. Weintraub, Lei Qian, Vennis Hong, et al.

  • Open Access

    Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States

    by J. Bradley Layton, Patricia C. Lloyd, Lauren S. Peetluk, Yixin Jiao, Djeneba Audrey Djibo, Joann F. Gruber, Jie Deng, Christine Bui, An-Chi Lo, Rachel P. Ogilvie, et al.

    With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID 19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID 19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID 19 and hospital/emergency department (ED)-diagnosed COVID 19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID 19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID 19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically-diagnosed and up to 9 months for hospital/ED-diagnosed COVID 19. VE differed by brand and variant era. Additional real-world research is needed as new variants and recommendations for updated vaccines have evolved.

  • Open Access

    Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United States

    by Rachel P. Ogilvie, J. Bradley Layton, Patricia C. Lloyd, Yixin Jiao, Djeneba Audrey Djibo, Hui Lee Wong, Joann F. Gruber, Ron Parambi, Jie Deng, Michael Miller, et al.

    Importance COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. Objective To estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children. Design A cohort study of children aged 5–17 years vaccinated with BNT162b2 matched with unvaccinated children. Setting Participants identified in Optum and CVS Health insurance administrative claims databases were linked with Immunization Information System (IIS) COVID-19 vaccination records from 16 US jurisdictions between December 11, 2020, and May 31, 2022 (end date varied by database and IIS). Participants Vaccinated children were followed from their first BNT162b2 dose and matched to unvaccinated children on calendar date, US county of residence, and demographic and clinical factors. Censoring occurred if vaccinated children failed to receive a timely dose 2 or if unvaccinated children received any dose. Exposure BNT162b2 vaccinations were identified using IIS vaccination records and insurance claims. Main Outcomes and Measures Two COVID-19 outcome definitions were evaluated: COVID-19 diagnosis in any medical setting and COVID-19 diagnosis in hospitals/emergency departments (EDs). Propensity score-weighted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox proportional hazards models, and vaccine effectiveness (VE) was estimated as 1 minus HR. VE was estimated overall, within age subgroups, and within variant-specific eras. Sensitivity, negative control, and quantitative bias analyses evaluated various potential biases. Results There were 453,655 eligible vaccinated children one-to-one matched to unvaccinated comparators (mean age 12 years; 50% female). COVID-19 hospitalizations/ED visits were rare in children, regardless of vaccination status (Optum, 41.2 per 10,000 person-years; CVS Health, 44.1 per 10,000 person-years). Overall, vaccination was associated with reduced incidence of any medically diagnosed COVID-19 (meta-analyzed VE = 38% [95% CI, 36%-40%]) and hospital/ED–diagnosed COVID-19 (meta-analyzed VE = 61% [95% CI, 56%-65%]). VE estimates were lowest among children 5–11 years and during the omicron variant era. Conclusions and Relevance Receipt of a complete BNT162b2 vaccine primary series was associated with overall reduced medically diagnosed COVID-19 and hospital/ED–diagnosed COVID-19 in children; observed VE estimates differed by age group and variant era. Question Does receiving a complete primary series of monovalent BNT162b2 COVID-19 vaccine reduce COVID-19 diagnoses and ED visits/hospitalizations in children aged 5–17 years? Findings In this cohort study evaluating vaccination records and medical encounters from 827,149 children, recipients of a complete primary series of BNT162b2 generally had lower rates of COVID-19 diagnoses and ED visits/hospitalizations than unvaccinated children. Vaccine effectiveness was lower in children aged 5–11 years and during omicron variant predominance. Meaning Receiving a primary series of monovalent BNT162b2 COVID-19 vaccine is effective in preventing COVID-19 diagnoses; changing variants and younger age groups may require further evaluations.

  • Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.

    by Azadeh Shoaibi, Patricia C. Lloyd, Hui-Lee Wong, Tainya C. Clarke, Yoganand Chillarige, Rose Do, Mao Hu, Yixin Jiao, Andrew Kwist, Arnstein Lindaas, et al.


  • Immune globulin usage trends in commercially insured and Medicare populations, 2009–2019

    by Yixin Jiao, Keran Moll, Graça M. Dores, Ellen Tworkoski, Cindy Ke Zhou, Dorothy Scott, Hui‐Lee Wong, Kathryn Fingar, Timothy Burrell, Rowan McEvoy, et al.

    Background: Longitudinal patterns of immune globulins (IG) use have not been described in large populations. Understanding IG usage is important given potential supply limitations impacting individuals for whom IG is the sole life‐saving/health‐preserving therapy. The study describes US IG utilization patterns from 2009 to 2019.Study Design and Methods: Using IBM MarketScan commercial and Medicare claims data, we examined four metrics overall and by condition‐specific categories during 2009–2019: (1) IG administrations per 100,000 person‐years, (2) IG recipients per 100,000 enrollees, (3) average annual administrations per recipient, and (4) average annual dose per recipient.Results: In the commercial and Medicare populations respectively: IG administrations per 100,000 person‐years increased by 120% (213–470) and 144% (692–1693); IG recipients per 100,000 enrollees grew by 71% (24–42) and 102% (89–179); average annual administrations per recipient rose by 28% (8–10) and 19% (8–9); and average annual dose (grams) per recipient increased by 29% (384–497) and 34% (317–426). IG administrations associated with immunodeficiency (per 100,000 person‐years) increased by 154% (from 127 to 321) and 176% (from 365 to 1007). Autoimmune and neurologic conditions were associated with higher annual average administrations and dose than other conditions.Discussion: IG use increased, coinciding with a growth in the IG recipient population in the United States. Several conditions contributed to the trend, with the largest increase observed among immunodeficient individuals. Future investigations should assess changes in the demand for IVIG by disease state or indication and consider treatment effectiveness.


  • Open Access

    Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S

    by Azadeh Shoaibi, Patricia C. Lloyd, Hui-Lee Wong, Tainya C. Clarke, Yoganand Chillarige, Rose Do, Mao Hu, Yixin Jiao, Andrew Kwist, Arnstein Lindaas, et al.

    Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations. Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively. Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly. HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.